CLINICAL RESEARCH: HEART FAILURE
Beta-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada
David Johnson, MD*,
Yan Jin, MA ,
Hude Quan, MD, PhD and
Bibiana Cujec, MD ,*
* Division of Critical Care Medicine, University of Alberta, Alberta, Canada
Research and Evidence, Alberta Health and Wellness, Alberta, Canada
Department of Community Health Sciences, University of Calgary, Calgary, Canada
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
Manuscript received January 8, 2003;
revised manuscript received June 18, 2003,
accepted June 25, 2003.
* Reprint requests and correspondence: Dr. Bibiana Cujec, Division of Cardiology, University of Alberta, 2C2.39 WMC, Edmonton, Alberta, Canada T6G 2B7.
Bibiana.Cujec{at}ualberta.ca
OBJECTIVES: We sought to evaluate the common utilization of beta-blockers and angiotensin-converting enzyme (ACE) inhibitors or receptor blockers (RBs) in congestive heart failure (CHF).
BACKGROUND: We assessed the association between prescriptions of beta-blockers and ACE inhibitors or RBs within three months after hospitalization and mortality for newly diagnosed CHF in Alberta, Canada seniors (age 65 years and older).
METHODS: Administrative hospital discharge abstracts and drug data during October 1, 1994, to December 31, 1999, were analyzed.
RESULTS: There were 11,854 hospitalizations for newly diagnosed CHF. The use of beta-blockers within three months after hospitalization increased from 7.3% in 1994–1995 to 20.9% in 1999–2000. The use of ACE inhibitor or RBs within three months after hospitalization increased from 31.0% in 1994–1995 to 44.3% in 1999–2000. Adjusted one-year mortality was lower in seniors with prescriptions for beta-blockers (18.2%; 95% confidence interval [CI] 14.2 to 22.2), ACE inhibitors/RBs (22.3%; 95% CI 20.9 to 23.7), or both (16.6%; 95% CI 13.3 to 20.0), compared with those with no prescriptions (29.9%; 95% CI 28.8 to 31.0). Absolute adjusted risk reduction comparing no prescription with prescription of both beta-blockers or ACE inhibitors/RBs was 13.3% for a relative adjusted risk reduction of 44%.
CONCLUSIONS: This study of incident CHF hospitalizations among seniors demonstrates an association between decreased mortality and the use of beta-blockers, ACE inhibitors/RBs, or combination of both. The effectiveness of beta-blockers and ACE inhibitors/RBs for CHF should be more broadly tested in clinical trials that recruit older patients and those with diastolic dysfunction.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | CHF | = congestive heart failure | | CPX | = Canadian Classification of Procedures | | ICD-9-CM | = International Classification of Disease- Ninth Revision-Clinical Modification | | RB | = receptor blocker |
|
This article has been cited by other articles:
|
|
|
|
 
A. M. Clark, C. N. Freydberg, F. A. McAlister, R. T. Tsuyuki, P. W. Armstrong, and L. A. Strain
Patient and informal caregivers' knowledge of heart failure: necessary but insufficient for effective self-care
Eur J Heart Fail,
June 1, 2009;
11(6):
617 - 621.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Komajda, O. Hanon, M. Hochadel, J. L. Lopez-Sendon, F. Follath, P. Ponikowski, V.-P. Harjola, H. Drexler, K. Dickstein, L. Tavazzi, et al.
Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II
Eur. Heart J.,
February 2, 2009;
30(4):
478 - 486.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Huang, P Loewen, T Pelletier, J Slater, and M Chung
Implementation of proven interventions in general medical inpatients: development and evaluation of a new quality indicator for drug therapy
Qual. Saf. Health Care,
August 1, 2008;
17(4):
269 - 274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Komajda, O. Hanon, M. Hochadel, F. Follath, K. Swedberg, A. Gitt, and J. G.F. Cleland
Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I
Eur. Heart J.,
June 1, 2007;
28(11):
1310 - 1318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Dobre, D. J. van Veldhuisen, M. J.L. DeJongste, C. Lucas, G. Cleuren, R. Sanderman, A. V. Ranchor, and F. M. Haaijer-Ruskamp
Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival
Eur J Heart Fail,
March 1, 2007;
9(3):
280 - 286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Hillis, K. J. Zehr, A. W. Williams, H. V. Schaff, T. A. Orzulak, R. C. Daly, C. J. Mullany, R. J. Rodeheffer, and J. K. Oh
Outcome of Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting: Renal Function and Mortality After 3.8 Years
Circulation,
July 4, 2006;
114(1_suppl):
I-414 - I-419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Arzt and T. D. Bradley
Treatment of Sleep Apnea in Heart Failure
Am. J. Respir. Crit. Care Med.,
June 15, 2006;
173(12):
1300 - 1308.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Lee, J. V. Tu, D. N. Juurlink, D. A. Alter, D. T. Ko, P. C. Austin, A. Chong, T. A. Stukel, D. Levy, and A. Laupacis
Risk-Treatment Mismatch in the Pharmacotherapy of Heart Failure
JAMA,
September 14, 2005;
294(10):
1240 - 1247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Galbreath, R. A. Krasuski, B. Smith, K. C. Stajduhar, M. D. Kwan, R. Ellis, and G. L. Freeman
Long-Term Healthcare and Cost Outcomes of Disease Management in a Large, Randomized, Community-Based Population With Heart Failure
Circulation,
December 7, 2004;
110(23):
3518 - 3526.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Rich
Are Angiotensin-Converting Enzyme Inhibitors Indicated for the Routine Treatment of Elderly Heart Failure Patients?
J. Gerontol. A Biol. Sci. Med. Sci.,
July 1, 2004;
59(7):
M713 - M715.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Thornton and A. Ahmed
Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure
J. Am. Coll. Cardiol.,
April 7, 2004;
43(7):
1333 - 1333.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Johnson and B. Cujec
Reply
J. Am. Coll. Cardiol.,
April 7, 2004;
43(7):
1333 - 1334.
[Full Text]
[PDF]
|
|
|
|
